Shunichi Morimoto
Geen lopende functies
Vermogen: 2 M $ op 30-04-2024
Profiel
Shunichi Morimoto was the Chairman of Institute of Immunology Co., Ltd.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
PHOENIXBIO CO., LTD.
12.56% | 31-03-2023 | 506 000 ( 12.56% ) | 2 M $ | 30-04-2024 |
Eerdere bekende functies van Shunichi Morimoto
| Bedrijven | Functie | Einde |
|---|---|---|
Institute of Immunology Co., Ltd.
 Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | Voorzitter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | Health Technology |
